RosenbergS. A.LotzeM. T.MuulL. M.ChangA. E.EttinghausenS. E.MatoryY. L.ShiloniE.VettoJ. T.SeippC. A.SimpsonC.ReichertC. M.1985. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. The New England Journal of Medicine, 313, 23: 1485–1492.
2.
LotzeM. T.MatoryY. L.EttinghausenS. E.RaynerA. A.SharrowS. O.SeippC. A.CusterM. C.RosenbergS. A.1985. In vivo administration of purified human interleukin-2. The Journal of Immunology, 135, 4: 2865–2874.
3.
RosenbergS. A.SpiessP.LafreniereR.1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 233: 1318–1321.
4.
DinarelloC. A.MierJ. W.1986. Interleukins. 1986. Ann. Rew. Med.37: 173–178.
5.
NakataK.KashimotoS.YoshidaH.OkuT.NakauraS.1988. Augmented antitumor effect of recombinant human interleukin-1α by indomethacin. Cancer Res. 48, 584–588.
6.
SmithR. J.BowmanB. J.SpezialeS. C.1986. Interleukin-1 stimulates granule exocytosis from human neutrophils. Int. J. Immunopharmacol., 8, 1: 33–40.
7.
PasswellJ. H.DayerJ. M.MerlerE.1979. Increased prostaglandin production by human monocytes after membrane receptor activation. 1979. J. of Immunology, 123, 1: 115–120.
RobinsonD. R.1983. Prostaglandins and the mechanism of action of anti-inflammatory drugs. Ann. J. Med., 75 (S), 26–31.
10.
GoodwinJ. S.1984. Mechanism of action of non-steroidal anti-inflammatory agents. Ann. J. Med., 77 (S), 57–64.
11.
BartoliniG.OrlandiM.ChiricoloM.MinghettiL.GuerriniF.FidanM.FranceschiC.TomasV.1986. Regulation of thromboxane A2 biosynthesis in platelet-free human monocytes and the possible role of polypeptide growth factor (s) in the induction of cyclooxygenase system. Bioch. Bioph. Acta876: 486–493.
12.
DinarelloC. A.1988. Biology of interleukin-1. Faseb J., 2: 108–115.
13.
HoriT.ShibataM.NakashimaT.YamasakiM.AsamiA.AsamiT.KogaH.1988. Effects of interleukin-1 and arachidonate on the preoptic and anterior hypothalamic neurons. Brain Res. Bull., 20: 75–82.
14.
ContiP.RealeM.AngelettiP. U.DinarelloC. A.1988. Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon alpha or gamma, human recombinant interleukin-2 and indomethacin. Int. J. Immunopharmacol., 10: 907–911.
15.
ContiP.CifoneM. G.RealeM.FieschiC.DinarelloC. A.1986. In vitro enhanced thromboxane B2 release by polymorphonuclear leukocytes and macrophages after treatment with human recombinant interleukin. Prostaglandins, 32: 112–5.
16.
ContiP.RealeM.FioreS.CancelliA.BarbacaneR. C.BongrazioM.PanaraM. R.DinarelloC. A.1988. Interleukin-1 and TNF in combination cause a synergistic aggregation of neutrophils. 9th European Immunology Meeting. Rome, September14–17.
17.
KappA.Zeck-KappG.DannerM.LugerT. A.1988. Human granulocyte-macrophage colony stimulating factor: An effective direct activator of human polymorphonuclear neutrophilic granulocytes. The J. of Inv. Dermatology, 91, 1: 49–55.
18.
AndusT.GeigerT.HiranoT.KishimotoT.Tran-ThiT.DeckerK.HeinrichP.1988. Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur. J. Biochem., 173: 287–293.
19.
BorishL.O'ReillyD.KlempnerM. S.RocklinR. E.1986. Leukocyte inhibitory factor (LIF) potentiates neutrophil response to formyl-methionyl-leucyl-phenylalanine. J. of Immunology, 137: 1897–1903, vol. 6.
20.
GoetzlE. J.PickettW. C.1981. Novel structural determinants of the human neutrophil chemotactic activity of leukotrien B. J. Exp. Med., 153: 482–487.
